CareDx (NASDAQ:CDNA) Reaches New 1-Year High Following Analyst Upgrade

Posted by Geri Gentry on Jul 18th, 2026

CareDx, Inc. (NASDAQ:CDNA – Get Free Report) shares hit a new 52-week high on Thursday after BTIG Research raised their price target on the stock from $28.00 to $45.00. BTIG Research currently has a buy rating on the stock. CareDx traded as high as $35.50 and last traded at $36.5450, with a volume of 137228 shares changing hands. The stock had previously closed at $29.75.

CDNA has been the topic of several other reports. Craig Hallum reiterated a “hold” rating and set a $35.00 target price on shares of CareDx in a research note on Thursday. Wall Street Zen upgraded CareDx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 3rd. Finally, Weiss Ratings raised CareDx from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, June 26th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $33.67.

Get Our Latest Research Report on CareDx

Insider Buying and Selling

In other news, Director Hannah Valantine sold 12,103 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the transaction, the director directly owned 36,686 shares of the company’s stock, valued at $847,813.46. This represents a 24.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $29.24, for a total value of $1,166,676.00. Following the transaction, the chief executive officer directly owned 661,959 shares in the company, valued at $19,355,681.16. The trade was a 5.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 78,936 shares of company stock worth $2,093,708. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in CareDx by 1.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock valued at $739,000 after purchasing an additional 711 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of CareDx by 4.8% during the second quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after buying an additional 1,280 shares during the period. Quarry LP bought a new position in shares of CareDx during the fourth quarter valued at approximately $25,000. Allspring Global Investments Holdings LLC grew its stake in shares of CareDx by 9.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company’s stock valued at $365,000 after buying an additional 1,675 shares during the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in shares of CareDx in the third quarter worth approximately $31,000.

CareDx Price Performance

The stock has a market capitalization of $2.05 billion, a PE ratio of -248.31 and a beta of 2.43. The firm has a fifty day moving average price of $25.21 and a two-hundred day moving average price of $21.27.

CareDx (NASDAQ:CDNA – Get Free Report) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.23. The company had revenue of $117.70 million during the quarter, compared to analysts’ expectations of $102.03 million. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.CareDx’s revenue was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.09 EPS. On average, research analysts expect that CareDx, Inc. will post 0.22 earnings per share for the current fiscal year.

CareDx Company Profile

(Get Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.